Cardiome Pharma Corp. announced that the company has entered into a distribution agreement with Logista Pharma S.A., headquartered in Madrid, Spain, to distribute Brinavess (vernakalant IV) within the Spanish market.

 

“We are pleased to have entered into this agreement with Logista Pharma to distribute Brinavess to our Spanish customers,” said Karim Lalji, Cardiome’s chief commercial officer. “Brinavess pricing has been approved nationally by La Comisión Interministerial de Precios de los Medicamentos, Spain’s official medical drug pricing and reimbursement agency, which is significant for gaining market acceptance. Spain is a key growth market for Brinavess and our new relationship with Logista Pharma is one of many steps towards building a successful brand in this country.”

 

The state-of-the-art processes developed by Logista Pharma will ensure secure and timely fulfillment of Brinavess orders to all our hospital customers.

 

Financial details of the agreement were not disclosed.

 

Date: March 19, 2014

Source: Cardiome